Abstract:In recent years, gene therapy has been raising hopes toward viable treatment strategies for rare genetic diseases for which there has been almost exclusively supportive treatment. We here review this progress at the pre-clinical and clinical trial levels as well as market approvals within diseases that specifically affect the brain and spinal cord, including degenerative, developmental, lysosomal storage, and metabolic disorders. The field reached an unprecedented milestone when Zolgensma® (onasemnogene abeparvovec) was approved by the FDA and EMA for in vivo adeno-associated virus-mediated gene replacement therapy for spinal muscular atrophy. Shortly after EMA approved Libmeldy®, an ex vivo gene therapy with lentivirus vector-transduced autologous CD34-positive stem cells, for treatment of metachromatic leukodystrophy. These successes could be the first of many more new gene therapies in development that mostly target loss-of-function mutation diseases with gene replacement (e.g., Batten disease, mucopolysaccharidoses, gangliosidoses) or, less frequently, gain-of-toxic-function mutation diseases by gene therapeutic silencing of pathologic genes (e.g., amyotrophic lateral sclerosis, Huntington's disease). In addition, the use of genome editing as a gene therapy is being explored for some diseases, but this has so far only reached clinical testing in the treatment of mucopolysaccharidoses. Based on the large number of planned, ongoing, and completed clinical trials for rare genetic central nervous system diseases, it can be expected that several novel gene therapies will be approved and become available within the near future. Essential for this to happen is the in depth characterization of short- and long-term effects, safety aspects, and pharmacodynamics of the applied gene therapy platforms.

Gene-based therapies for neuromuscular disorders

Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle

Molecular mechanisms and therapeutic strategies for neuromuscular diseases

Gene therapy for Duchenne muscular dystrophy: an update on the latest clinical developments

Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease

Gene Therapy: A Promising Approach to Treating Spinal Muscular Atrophy

Genome engineering: a new approach to gene therapy for neuromuscular disorders

Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges

Recent developments and industry interest in gene therapy for Duchenne muscular dystrophy

Gene therapy for mitochondrial disorders

Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord

Current and emerging targeted therapies for spinal muscular atrophy

Gene therapies for CMT neuropathies: from the bench to the clinic

Recent advances in the treatment of Charcot‐Marie‐Tooth neuropathies

Genetic therapies and respiratory outcomes in patients with neuromuscular disease

Current Clinical Applications of In Vivo Gene Therapy with AAVs

Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care

Gene-based therapy for the treatment of spinal muscular atrophy types 1 and 2 : a systematic review and meta-analysis

Gene therapy and other novel treatment approaches for Charcot-Marie-Tooth disease

Gene therapy for CNS disorders: modalities, delivery and translational challenges

Toward the correction of muscular dystrophy by gene editing